Drug Profile
Research programme: cancer vaccines - Immatics N.V./Roche
Alternative Names: Colorectal cancer ImmunoBody vaccines - ImmaticsN.V./Scancell; Gastric cancer vaccine - Immatics N.V.; IMA 930; IMA 942; IMA 962; Non-small cell lung cancer vaccine - Immatics N.V.; TUMAP-based cancer vaccines - Immatics N.V/RocheLatest Information Update: 07 Jul 2020
Price :
$50
*
At a glance
- Originator immatics biotechnologies GmbH
- Developer Immatics N.V.; Roche
- Class Cancer vaccines; Peptide vaccines; Peptides
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gastric cancer; Non-small cell lung cancer; Prostate cancer
Most Recent Events
- 01 Jul 2020 Immatics N.V and Immatics Biotechnologies GmbH combined to form Immatics N.V.
- 28 Jan 2020 No recent reports of development identified for preclinical development in Gastric-cancer in Germany (Intradermal, Injection)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in Germany (Intradermal, Injection)